EndoPredict versus uPA/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters

Breast J. 2019 May;25(3):450-454. doi: 10.1111/tbj.13258. Epub 2019 Apr 18.

Abstract

We retrospectively investigated concordance of EndoPredict (EPclin) with urokinase plasminogen activator and plasminogen activator inhibitor-1 (uPA/PAI-1) in 72 breast cancer patients and compared the results with grading, molecular subtype and chemotherapy recommendation. Compared to uPA/PAI-1, EPclin proved to be more conservative concerning correlation with clinicopathological parameters and was significantly associated with the recommendation of adjuvant chemotherapy.

Keywords: breast cancer; prognosis; proteases.

Publication types

  • Comparative Study

MeSH terms

  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / genetics
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology*
  • Chemotherapy, Adjuvant
  • Female
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Middle Aged
  • Plasminogen Activator Inhibitor 1 / analysis*
  • Retrospective Studies
  • Urokinase-Type Plasminogen Activator / analysis*

Substances

  • Biomarkers, Tumor
  • Plasminogen Activator Inhibitor 1
  • SERPINE1 protein, human
  • Urokinase-Type Plasminogen Activator